Barr Laboratories'

(BRL)

application to make and sell a generic version of the acne drug Accutane was cleared by the Food and Drug Administration.

The company said it will begin marketing in May a generic version of Roche Pharmaceutical's Accutane capsules in 10-, 20- and 40-milligram formulations under the name Claravis. Claravis will be used for the treatment of severe recalcitrant nodular acne, the company said.

TheStreet Recommends

Recently, shares were up 0.2% to $55.51 on the news.

Claravis will compete against Accutane, which had total annual sales of about $523 million for the 12 months ended January 2003, the company said.

Barr Laboratories is a specialty pharmaceuticals company based in Pomona, N.Y.